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FDA seeks to modify regulation of medical devices: challenges for resource-poor settings? 
10 September 2010 
The Centre for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA) 
has recently decided to review the assessments on the 510(k) premarket process and to proactively 
facilitate medical device innovation (1). 
Such initiatives are certainly challenging. In particular, the initiative on device innovation aims at 
"identifying unmet public health needs" and at facilitating the development or redesign of a device to 
address those needs", and it could bring potential benefits also for the patients in resource-poor 
settings. In fact, "unmet public health needs" are defined in the FDA website (1) as "those illnesses and 
injuries that are serious or have moderate adverse impact on health, but affect many individuals; or that 
could be cured, significantly improved or prevented by the development or redesign of a device; or for 
which the device is not being developed or redesigned due to barriers that the Federal Government can 
directly or indirectly remove or minimize". Actually, many of those diseases that "could be cured, 
significantly improved or prevented by the development or redesign of a device" are neglected diseases, 
mainly prevalent in resource-poor countries and for which in vitro diagnostics are either lacking or they 
are inappropriate for use in poor settings. Among them, we can mention the Chagas disease, for which a 
test of cure is still missing; visceral leishmaniasis, where improvement is needed for test case-
management; and tuberculosis, a high-burden disease whose management in public health settings in 
developing countries is seriously challenged by the lack of a point-of-care test appropriate for resource- 
poor contexts (2-3). 
The lack of research and development is not the only barrier to quality diagnosis and cure in resource-
limited settings. The presence, on those markets, of in vitro diagnostics whose quality has not been 
verified according to stringent criteria may also represent a problem (4). This may be due to poor 
regulatory oversight (5) and to insufficient national and international guidance on their design and 
quality assurance. When regulatory oversight is insufficient, the FDA approval is often taken as proof of 
quality for diagnostic products (specifically, the 510(k) premarket process, where the majority of 
parasitic test fall in, is often referred to) (4). In this perspective, the planned review of the assessments 
on the 510(k) premarket process can be beneficial for developing countries, especially if accompanied 
by transparent information -sharing on quality requirements for manufacturing and verifying medical 
and diagnostic devices. The same recommendation would apply to the European "CE mark", which is 
also often taken as proof of quality for diagnostics in resource-poor countries.  
Developing innovative in vitro diagnostics, and assuring the quality of those put on the market, are 
equally crucial measures to improve the quality of disease management in developing countries, so 
contributing to reduce the existing North-South gap in access to health. 
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